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including our own sample. In this report, we present results
of resequencing the GRM7 gene in 32 bipolar samples and 32
random controls selected from 553 bipolar cases and 547 control
samples (UCL1). Novel and potential etiological base pair
changes discovered by resequencingwere genotyped in the entire
UCL case–control sample. We also report on the association
betweenGRM7 andBP ina second sampleof 593patients and642
controls (UCL2). The threemost significantly associated SNPs in
the originalUCL1BPGWAS samplewere genotyped in theUCL2
sample, of which none were associated. After combining the
genotype data for the two samples only two (rs1508724 and
rs6769814) of the original three SNP markers remained signifi-
cantly associated with BP. DNA sequencing revealed mutations
in three cases which were absent in control subjects. A 30-UTR
SNP rs56173829was found to be significantly associated with BP
in the whole UCL sample (P¼ 0.035; OR¼ 0.482), the rare allele
being less common in cases compared to controls. Bioinformatic
analyses predicted a change in the centroid secondary structure
of RNA and alterations in the miRNA binding sites for the
mutated base of rs56173829. We also validated two deletions
and a duplication within GRM7 using quantitative-PCR which
provides further support for the pre-existing evidence that copy
number variants at GRM7may have a role in the etiology of BP.
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Bipolar disorder (BP) is diagnosed using operational criteria which
define episodes ofmania or hypomania with or without depression
and are considered as reliable and valid as most medical diagnoses
[Spitzer et al., 2012]. Bipolar and genetically related spectrum
disorders such as unipolar affective disorders have a heritability
of 89%with environmental effects limited to the specific or unique2014 The Authors. American Journal of Medical Genetics Part B:environment with no evidence for effects from the shared family
environment [McGuffin et al., 2003].
Metabotropic glutamate receptors (mGluRs) are G protein
coupled receptors which have a critical role in brain function.
mGluRs are present in all regions of the brain involved in learning,
memory, anxiety, and the perception of pain. They are highly
expressed in pre- and postsynaptic neurons in the cerebellum,
cerebral cortex, hippocampus, cingulate cortex, frontal cortex,
amygdala, hippocampus, and locus coeruleus [Shigemoto et al.,
1997; O’Connor et al., 2010]. mGluRs are involved in long-term
potentiation and long-term depression and have a vital role in
modulating glutamate release [Sanderson et al., 2011]. GRM7 is the
most highly conserved group III metabotropic glutamate receptorNeuropsychiatric Published by Wiley Periodicals, Inc. 365
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through inhibition of the second messenger adenylate cyclase
and postsynaptically decreases NMDA receptor activity [Gu
et al., 2012]. Presynaptic mGluR7 modulates the release of both
L-glutamate and GABA and is involved in excitability levels in
specific neuronal circuits, thereby influencing different emotional
states such as anxiety and depression as well as cognitive dysfunc-
tion [Swanson et al., 2005].
GRM7 is located on 3p26.1 and previous linkage studies have
implicated this chromosomal region 3p in BP [Kelsoe et al., 2001;
Fallin et al., 2005; Etain et al., 2006]. A recent comparative linkage
meta-analysis of all whole genome linkage studies of BP found
evidence of linkage at 3p25.3–3p22.1 using narrow (P¼ 0.0099)
and broad spectrum (P¼ 0.0060) diagnostic models of BP [Tang
et al., 2011]. Independent studiesbyBreenet al. [2011] andPergadia
et al. [2011] reported evidence for genetic linkage between major
depressivedisorder and chromosome3p26–p25withLODscores of
4.0 and 4.14, respectively.
Genetic association between markers at the GRM7 locus and BP
was reported by theWellcomeTrustCaseControlConsortiumwith
themost significantly associated SNP at P¼ 0.000097. A significant
associationwithin any one genomewide association study (GWAS)
has not been reported for GRM7. However, the involvement of
GRM7 as a bipolar affective disorder susceptibility locus has
accumulated in several independent studies [WTCCC, 2007; Sklar
et al., 2008; Alliey-Rodriguez et al., 2011]. A recent GWAS of
personality traits in bipolar patients found association for a
GRM7 SNP with the neuroticism-anxiety scale of the Zucker-
man–Kuhlman Personality Questionnaire (rs13080594, P¼ 7.68
 107) [Alliey-Rodriguez et al., 2011]. A GWAS of major depres-
sion and meta-analyses have also demonstrated association with
GRM7 [Sullivan et al., 2009;Muglia et al., 2010; Shi et al., 2011; Shyn
et al., 2011]. Comorbidity between bipolar I disorder and ADHD
has been well documented previously [Faraone et al., 2012]. A
Korean study reported association between the GRM7 polymor-
phism rs37952452 and attention-deficit hyperactivity disorder
(ADHD) using the transmission disequilibrium method in trios
[Park et al., 2013]. The contribution of CNVs in the psychiatric
disorders has been appreciated only recently with the implementa-
tion of array technologies that enable genome-wide determination
ofCNVs. Two studies of CNVs inBP reported no overall increase in
CNVload in cases and found that controls had a significant excess of
CNVs [Grozeva et al., 2010;McQuillin et al., 2011]. In a third study,
a nominally significant increase in singleton CNVs in BP cases
compared with controls was found [Zhang et al., 2009]. Deletions
and duplications inGRM7were found in the UCL1 bipolar sample
aswell [McQuillin et al., 2011]. Rare CNVs occurringwithinGRM7
have been documented in patients with other psychiatric disorder
patients, such as mood disorder [Saus et al., 2010], schizophrenia
[Walsh et al., 2008] and ADHD [Elia et al., 2012]. A growing body
of evidence suggests a strong relationship between mGluR7 func-
tion and the action of antidepressants and mood-stabilizers
[Palucha, 2006]. Fabbri et al. [2013] investigated the modulation
of early antidepressant efficacy by glutamatergic gene variants in the
STARD sample and found that a GRM7 SNP rs1083801 was
associated with early response under a recessive model. Evidence
from genetic, pharmacological, and animal studies suggests aconnection between GRM7 and BP and other neuropsychiatric
disorders. Themain aimof this studywas to build upon the positive
allelic association studies of GRM7 we previously published [Sklar
et al., 2008] by resequencing exons and flanking regions of
the GRM7 gene in bipolar cases selected for inheriting a disease
haplotype discovered in original GWAS dataset in order to find
potential etiological base pair changes within GRM7. Any novel
SNPs or mutations likely to be pathogenic were then genotyped in
theUCL1 sample and a new independent bipolar sample (UCL2) in
order to test for allelic association with BP. Coupled with this we
also attempted to validate the three CNVs identified in the original
UCL1 sample using QRT-PCR.MATERIALS AND METHODS
UCL Bipolar Case–Control Sample
The study included 1,099 affected bipolar research subjects and
1,152 normal comparison subjects that were sampled in 2 cohorts.
The first cohort called UCL1 comprised of 506 bipolar I cases and
510 normal comparison subjects which were subjected to a GWAS
resulting in publications focusing on the top association hits [Sklar
et al., 2008]. The second cohort (UCL2) comprised of 409 bipolar I
(69%) and 184 bipolar II research subjects, and 642 normal control
subjects. The sample of 1,152 normal comparison subjects com-
prised 672whowere screened for an absence of psychiatric disorders
plus 480 unscreened British normal volunteers provided by Euro-
pean Collection of Animal Cell Cultures (ECACC). All cases and
controls were selected to be of UK or Irish ancestry. UK National
Health Service multicenter and local research ethics approvals were
obtained and signed informed consent was given by all subjects. All
UCL bipolar subjects and the psychiatrically screened control sub-
jects were interviewed by a psychiatrist using the lifetime version of
the Schizophrenia and Affective Disorders Schedule (SADS-L)
[Spitzer et al., 1975]. The control subjects were selected if they
were found to be normal after screening with the SADS-L interview
and it was established that they had no first degree relatives with
any mental disorder. All bipolar subjects were found to have BP
diagnoses according to Research Diagnostic Criteria [Spitzer
et al., 1975]. All the bipolar research subjects were also rated with
the 90-item OPCRIT checklist [McGuffin et al., 1991]. DNA was
obtained fromblood samples for the cases and controls inUCL1and
from saliva samples for the cases inUCL2.DNAwas extracted for all
UCL samples using methods we have published previously [Pereira
et al., 2011; Kandaswamy et al., 2013].Detection and Evaluation of New Variants
GRM7 failed to reach genome-wide significance in the UCL1 BP
GWAS and thus was not reported in the main findings of the study
[Ferreira et al., 2008; Sklar et al., 2008]. A list of all the variants in
GRM7 genotyped in the UCL1 BP GWAS is reported in
Supplementary Table SI and the most significantly associated
GRM7 marker was the SNP rs1508724 [P¼ 0.0028; OR (95%
CI)¼ 1.33 (1.10–1.60)]. In the absence of any strongly associated
haplotype, DNA samples from 32 bipolar research subjects homo-
zygous or heterozygous for the rare allele of rs1508724 and alsowith
KANDASWAMY ET AL. 367an early age of onset of BP were selected for sequencing. Also, 32
random control subjects were selected for the sequencing ofGRM7.
Sequencingwas carriedout on15 exons included in all theGRM7
isoforms (UCSC, March 2006 assembly), exon/intron boundaries,
3 kb of the promoter region of the isoforms ENST00000486284
(main isoform) and ENST00000463676, and 1 kb promoter region
of the isoform ENST00000458641, 50-UTR and 30-UTR of the
GRM7 gene. The sequence of primers used for sequencing is listed
in Supplementary Table SII. Sequencing was done using the Big
Dye terminator v3.1 Cycle Sequencing kit (Applied Biosystems,
Warrington, UK) on an ABI 3730xl DNA Analyzer (Applied
Biosystems). Sequencing data was analyzed using the Staden Pack-
age [Staden, 1996]. Bioinformatic analysis to determine potentially
functional SNPs was carried out using the UCSC genome browser
(http://genome.ucsc.edu/), PolyPhen2 [Adzhubei et al., 2013]
RESCUE-ESE (http://genes.mit.edu/burgelab/rescue-ese/) [Fair-
brother et al., 2004], TESS (http://www.cbil.upenn.edu/cgi-bin/
tess/tess), UTRsite (http://utrsite.ba.itb.cnr.it/) [Grillo et al., 2010],
and RNAwebserver (rna.tbi.univie.ac.at/).Genotyping and Association Analysis
SNP genotyping for the three most significantly associated GRM7
SNPs, rs1508724, rs11710946, and rs6769814 in the UCL1 BP
GWAS was performed in the UCL2 samples by allele-specific
PCR at KBiosciences (KBiosciences, Hoddesdon, UK). Rare var-
iants or potentially etiological SNPs found by sequencing were
genotyped in-house using KASPar (KBiosciences) and High reso-
lution melting curve genotyping methods on a LightCycler 480
(Roche, West Sussex, UK) in both the UCL1 and UCL2 samples.
The primers used are listed in Supplementary Table SIII. For all
SNPs genotyped, 17% of samples were reduplicated to detect error
and confirm the reproducibility of genotypes. All these data were
analyzed to confirm Hardy–Weinberg equilibrium (HWE). Geno-
typic and allelic associations for SNPs were tested using x2 tests.
Haplotype tests of association were performed using Haploview
[Barrett, 2009]. Exploratory association analysis with imputed SNP
data was carried out on the combined UCL 1 and 2 data using
PLINK [Purcell et al., 2007].Data from the European samples in the
1000 genome project (20110521 genotype and haplotype release)
was used as a reference panel. Significance values shown for allTABLE I. SNP Association Results Wit
SNP
Position
(NCBI35/hg19)
UCL1
Allele counts (MAF)
P-BP CON
rs1508724 7241745 A 344 (0.34) A 280 (0.28) 0
G 668 (0.66) G 740 (0.72)
rs11710946 7246241 A 359 (0.36) A 430 (0.42) 0
G 653 (0.64) G 590 (0.58)
rs6769814 7251433 G 349 (0.35) G 297 (0.29) 0
A 657 (0.65) A 721 (0.71)
MAF, minor allele frequency; BP, bipolar; CON, control; OR, odds-ratio; P< 0.05 in bold.analyses are uncorrected for multiple testing and a cut-off signifi-
cance value of P< 0.05 was used. We performed a gene-based
burden test (C-alpha) [Neale et al., 2011]usingPLINK/SEQ(http://
atgu.mgh.harvard.edu/plinkseq/) that takes both protective and
risk alleles into account for testing association with the disease.
C-alpha test statistic P-value< 0.05 after 10,000 permutations was
considered significant.CNV Validation Using QRT-PCR
CNVs detected in the UCL1 samples were validated using Taq-
Man1 RNase P Copy Number Reference (CNR) Assay, Human
(Applied Biosystems). In the duplex, real-time PCR experiment, a
UPL primer-probe (Universal Probe Library, Roche Diagnostics
Ltd., UK) combination for the detection of the target gene, GRM7
(Supplementary Table SIV) and the TaqMan1RNase P CNR assay
for the detection of a reference gene, RNase P was used. For the
QRT-PCR reaction in a 384-well plate, 10 ng of template DNA,
0.2ml eachof 10mMforward and reverse primers and10mMprobe,
0.5ml of RNase P CNR assay mix, 5ml of LightCycler1 probes
master reaction mix and PCR water to a total volume of 10ml
was added. The cycling conditions used were 95˚C for 10min,
and 40 cycles of 95˚C for 15 sec and 60˚C for 1min. Data analysis
was performed using LightCycler relative quantification method
that is based on theDDCtmethod of QRT-PCR data analysis [Livak
and Schmittgen, 2001].RESULTS
Association Analysis
In our collaborative GWAS [Sklar et al., 2008], eight SNPs inGRM7
showed allelic association with BP in the UCL1 sample and the
most significantly associated SNP at this locus was rs1508724
(P¼ 0.0014) (Supplementary Table SI). We failed to replicate
the association of the three most significantly associated UCL1
GWAS SNPs, rs1508724, rs11710946, and rs6769814 in the UCL2
sample (Table I).On combining theUCL1 andUCL2 genotype data
for the three SNPs using PLINK, two SNPs, rs1508724 and
rs6769814, remained significant (Table II). We also performed
a meta-analysis to assess the association of these SNPs in theh GRM7 in the UCL Bipolar Samples
UCL2
value OR
Alleles counts (MAF)
P-value ORBP CON
.001 1.36 A 297 (0.29) A 270 (0.29) 0.979 1.00
G 723 (0.71) G 652 (0.71)
.002 0.75 A 399 (0.40) A 351 (0.38) 0.634 1.05
G 615 (0.60) G 567 (0.62)
.008 1.29 G 324 (0.31) G 275 (0.30) 0.571 1.06
A 716 (0.69) A 639 (0.70)
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368 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bcombined sample keeping account of heterogeneity. Only one SNP
rs6769814 remained significant as a result of meta-analysis
(Cochrane Q-statistic P-value of 0.2166, Fixed effects model;
P-value¼ 0.03506 and OR¼ 1.1544) (Table II). The heterogeneity
index for the other two SNPs rs1508724 and rs11710946 was
significantly high, 76.83 and 81.67, respectively. This suggested
that the UCL1 and UCL2 are not completely homogeneous
although both the samples were selected based on strict ancestry
based questionnaire.Sequencing
Detection of novel variants in GRM7 associated with BP was
pursued by resequencing all the exons in all the GRM7 isoforms,
exon/intron boundaries, 3 kb of the promoter region of the
isoforms ENST00000486284 and ENST00000463676, and 1 kb of
the promoter region of the isoform ENST00000458641, 50-UTR
and 30-UTR of the GRM7 gene in 32 bipolar cases and 32 random
controls. In total, we found 71 previously published and 10 novel
mutations in GRM7 (Supplementary Table SV). Most of the
published SNPs were of similar frequency in the sequenced cases
and controls (Supplementary Table SV), therefore, were not gen-
otyped further. Also, SNPs that were in complete LDwith theUCL1
BPGWASSNPswere not genotyped in the complete sample. Of the
novel mutations, three were single base substitutions, two STRs,
and five indels (Supplementary Table SV). Bioinformatic analysis
was carried out for the novel SNPs to predict their effect on the
structure and/or function of GRM7. Finally, based on increased
frequency in cases compared to controls in the sequencing panel, 18
SNPs were further genotyped in the complete UCL sample (UCL1
and UCL2). Among these, only rs56173829 was significantly asso-
ciated with BP in our sample (P¼ 0.035; OR¼ 0.4829) (Table III),
although it was less common in cases than controls and did not
survive multiple testing. The rare allele of the SNP rs56173829 was
present in 25/1821 alleles (1.4%) in control subjects versus 12/1810
(0.66%) in bipolar cases (Table III). The SNP rs56173829 is present
in the 30-UTR of the long isoform of GRM7 and may play an
important role in microRNA (miRNA) binding.
Additionally, three SNPswere present only in cases, rs138571076
(P¼ 0.0826) in three, GRM7_3f_7313045 in two and
GRM7_nPb_7467774 in only one bipolar patient. One of the novel
SNPs, GRM7_9c_7698252 was found in only one control. All these
SNPs are intronic in the GRM7 gene. The SNP rs712774 was
predicted to introduce a splice acceptor site using the Splice Site
Prediction by Neural Network (http://www.fruitfly.org/seq_tools/
splice.html) but was not associated with BP in our sample
(P¼ 0.853). Imputation using European sample data from 1000
genomes did not reveal any synonymous or functional SNPs that
were associatedwithBP (SupplementaryTable SVI). A gene burden
test did not provide any evidence of association with BD (C-alpha
P-value¼ 0.233).Haplotype Analysis
Weperformedhaplotype analysis on the combineddata fromall the
SNPs genotyped in GRM7 (UCL1 GWAS SNPs, the three GWAS
SNPs inUCL2, andSNPs foundbymutation screening inGRM7) in
TABLE III. Tests of Allelic Association of GRM7 SNPs Found by Resequencing, in the UCL Sample
SNP Position (NCBI35/hg19) Min/Maj allele MAF Genotype counts Allele counts P-value OR (95% CI)
rs114774914 6901783
Cases A/T 0.014 0/26/897 26/1820 0.268 0.75 (0.45–1.25)
Controls 0.019 0/35/901 35/1837
3_6901914 6901914
Cases C/CTCTT 0.022 1/39/885 41/1809 0.766 1.07 (0.69–1.67)
Controls 0.021 0/38/878 38/1794
rs62237228 6902167
Cases C/A 0.190 30/290/601 350/1492 0.228 1.11 (0.94–1.31)
Controls 0.175 27/267/625 321/1517
rs342034 6903601
Cases A/G 0.040 4/64/837 72/1738 0.351 1.18 (0.83–1.67)
Controls 0.034 1/60/852 62/1764
rs35106713 7188180
Cases C/T 0.008 0/14/915 14/1844 0.188 0.64 (0.33–1.25)
Controls 0.012 0/22/914 22/1850
rs140139253 7188396
Cases T/C 0.004 0/7/927 7/1861 0.787 1.16 (0.39–3.47)
Controls 0.003 0/6/924 6/1854
GRM7_3f_7313045 7338045
Cases G/A 0.001 0/2/927 2/1856 0.157 NA
Controls 0.000 0/0/932 0/1864
rs138571076 7338986
Cases G/A 0.002 0/3/926 3/1855 0.083 NA
Controls 0.000 0/0/932 0/1864
rs192193072 7339471
Cases A/G 0.001 0/2/926 2/1854 0.156 0.33 (0.07–1.65)
Controls 0.003 0/6/919 6/1844
rs712774 7456675
Cases C/T 0.263 81/392/580 554/1552 0.853 0.99 (0.86–1.14)
Controls 0.266 65/353/491 483/1335
GRM7_nPb_7467774 7492774
Cases T/C 0.001 0/1/923 1/1847 0.321 NA
Controls 0.000 0/0/909 0/1818
rs2229902 7494417
Cases T/A 0.447 185/445/282 815/1009 0.227 0.92 (0.81–1.05)
Controls 0.467 213/442/275 868/992
rs1965222 7603194
Cases T/C 0.128 18/235/805 271/1845 0.713 1.04 (0.86–1.25)
Controls 0.124 11/210/713 232/1636
GRM7_9c_7698252 7723252
Cases A/G 0.000 0/0/924 0/1848 0.319 NA
Controls 0.001 0/1/928 1/1857
rs140995942 7723896
Cases A/G 0.013 0/24/909 24/1842 0.371 0.78 (0.46–1.34)
Controls 0.016 0/30/885 30/1800
rs56173829 7782494
Cases A/T 0.007 0/12/899 12/1810 0.035 0.48 (0.24–0.96)
Controls 0.014 0/25/898 25/1821
rs17726576 7782551
Cases T/C 0.027 1/47/874 49/1795 0.763 1.07 (0.71–1.6)
Controls 0.025 0/46/874 46/1794
rs150288969 7783347
Cases A/G 0.008 0/14/910 14/1834 0.682 1.18 (0.54–2.55)
Controls 0.006 0/12/918 12/1848
Min, minor; Maj, major; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.
P values, 0.05 need to be in bold.
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significant haplotype (HAP_GRM7) associated with BP compris-
ing SNPs rs1400166, rs2875257, rs10510353, rs11708019,
rs1963265, rs1508724, rs9823996, rs11710946, and rs6769814
(P¼ 0.007) was less common in cases compared to controls
(2.2% and 4.3% in cases and controls, respectively) (data not
shown). Particularly, the SNPs driving the association of this
haplotype were the three most significantly associated SNPs in
UCL1 GWAS, rs1508724, rs11710946, and rs6769814. All the other
associated haplotypes, including HAP_GRM7, did not survive
permutation testing (data not shown).CNV Validation
McQuillin et al. [2011] reported an analysis of copy number
variants in the UCL1 bipolar research sample and found that the
overall rate of CNVs was significantly lower in cases compared
to controls. Both deletions and duplications of size >100 kb
were detected in GRM7 in the UCL1 sample (Supplementary
Table SVII). Deletions were present in two bipolar samples and
one control sample and a duplication was found in only one case
sample (Fig. 1).
We selected a deletion and a duplication involving a common
genomic region for validationusingQRT-PCRassay andTaqMan1
RNase PCNRAssay, Human (Applied Biosystems). In the RNase P
CNR assay, four individuals, two with a deletion, one with dupli-
cation, and twoCNVnegative control individuals were tested using
primerpairs designed todetect duplication anddeletion in the same
assay. Replicable results were obtainedwith all the four primer pairs
tested and the CNVswere confirmed in the respective UCL samples
(Supplementary Fig. S1).DISCUSSION
The GRM7 SNP markers found to be associated with BP in the
UCL1 sample could not be replicated in the UCL2 sample. This can
be explained by the presence of heterogeneity even within a single
ancestral (UK and Irish) group of people affected by BP. The
presence and the proportion of several other disease haplotypes
in GRM7 increasing susceptibility to BP in different populations
maymake it difficult to replicate findings even if the effect ofGRM7
is widespread. Another limitation may be that the replication
sample was not large enough to detect the expected level of
association with GRM7. Nonetheless, two of the previously associ-Scale
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FIG. 1. CNVs occurring in GRM7 in UCL1ated SNPs, rs1508724 and rs6769814, inUCL1 remained significant
when we combined genotype data of the UCL1 and UCL2 samples
using PLINK. Resequencing of GRM7 in the selected bipolar cases
detected a 30-UTR variant, rs56173829, which was significantly
associated with BP. This variant was less common in cases com-
pared to controls. Variants in the 30-UTR play an important role
in the regulation of translation by means of miRNA binding
sites. Additionally, we found two novel singleton mutations
(GRM7_3f_7313045, GRM7_nPb_7467774) and one previously
published SNP (rs138571076) that were only present in cases
and not observed in control volunteers. We used bi-directional
C-alpha test rare variant aggregate approach to test for gene-level
association between bipolar cases and controls. Although we did
not find any evidence of a greater burden of the rare variants in
GRM7 among bipolar cases compared to controls in our study it
might be due to the small sample size considering only 32 bipolar
samples were sequenced in our study.
Alternative splicing in GRM7 results in five isoforms character-
ized by different C-terminals. The rs56173829 variant is located in
the 30-UTR of the long isoform of GRM7 (NM_181874;
ENST00000486284). RNA webserver was used to predict the sec-
ondary structure of the wild type and mutant 30-UTR containing
SNP rs56173829. The RNA webserver produced two structures—
minimumfree energy (MFE) and centroid secondary structure. The
MFE structure of an RNA sequence is the secondary structure that
contributes a minimum of free energy whereas the centroid struc-
ture of the same is the secondary structure with minimal base pair
distance to all other secondary structures in the Boltzmann ensem-
ble. The predicted centroid secondary structures for the wild-type
30-UTR was altered by the introduction of the SNP rs56173829,
however, the MFE structures for both were not dissimilar (Sup-
plementary Figs. S2 and S3). The cis-regulatory elements in the 30-
UTR of mRNAs have been reported to influence translation and
cause diseases. Translation de-regulation and disorders resulting
from mutations affecting the termination codon, polyadenylation
signal, and secondary structure of 30-UTR of mRNA have been
documented [Chatterjee and Pal, 2009]. A correlation between the
functionality of 30-UTR variants and alterations in the predicted
mRNA secondary structure was reported in a study by Chen et al.
[2006] on 83 disease associated 30-UTR variants of various human
mRNAs.
miRNAs are 21–22 nucleotides long, single-stranded, and bind
to 30-UTRs of particular mRNAs through partially complementary
sequences and prevents the mRNAs from being translated intohg18
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GWAS sample [McQuillin et al., 2011].
KANDASWAMY ET AL. 371proteins. Multiple types of miRNAs can cooperate to suppress
translation of a singlemRNA, and a singlemiRNA can interact with
multiple types of miRNAs, thereby regulating the protein expres-
sion of different genes [Filipowicz et al., 2008]. RegRNA (http://
regrna.mbc.nctu.edu.tw/html/prediction.html) is a web server that
facilitates the analysis of regulatory RNA motifs. The software
predicted differential miRNA binding of the wild type and mutant
30-UTR containing the rs56173829 base. Target scan and the UCSC
genome browser do not predict anymiRNA binding sites involving
the nucleotide and the sequence around it. In a study by Zhou et al.
[2009] chronic treatmentof primary cultureswithmood stabilizers,
VPA or lithium elevated levels of GRM7 and lowered levels of miR-
34a. Incubation of primary hippocampal culture with miR-34a
precursor significantly reduced GRM7 protein levels whereas, with
anti-miR miRNA-34a inhibitor, significantly increased GRM7
protein levels were observed. These results suggested that mood
stabilizers produce a part of their behavioral effects through mech-
anisms including modulation of protein levels through miRNAs
such as miR-34a [Zhou et al., 2009].
CNVs have been implicated in the pathogenesis of many psy-
chiatric disorders however CNVs associated with BP have been
difficult to find [Zhang et al., 2009; Grozeva et al., 2010; McQuillin
et al., 2011]. We confirmed the presence of two deletions and a
duplication in the UCL1 sample. Functional studies investigating
the possible role of these CNVs are required to shed more light on
their involvement in the disorder.
In conclusion, we found a 30-UTR variant in GRM7 that was
significantly associated with BP. Bioinformatic analyses predicted
that the rs56173829 variant influenced the centroid secondary
structure of the RNA and also altered the binding site of a few
miRNAs. However, results from these in silico analyses should be
interpreted with caution as these are based on mathematical
algorithms instead of expression studies. Thus, functional assays
need to be carried out to assess the role of the 30-UTR variant on
GRM7 gene expression. The case-only novel mutations reported in
our study also warrant further investigation in other populations in
order to understand their distribution and involvement in the
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